// App-Quantinova.ai

: AN ORAL, CHEMOTHERAPY-FREE REGIMEN (DASATINIB PLUS PREDNISONE) AS INDUCTION AND CONSOLIDATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Xueying Li

Principal Investigators

  • JieJing Qian

  • Min Yang

  • Yi Zhang

  • ShaSha Wang

  • HaiTao Meng

  • WenJuan Yu

  • HongYan Tong

  • XiuJin Ye

  • Jie Jin

  • HongHu Zhu

Medical Centers

  • The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

  • Department of Cardiology, First Affiliated Hospital of Zhejiang University, School of Medicine,China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Prednisone

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved